Related Experiment Videos
Therapy of obstetrical infections with moxalactam
Abstract:
We evaluated moxalactam in 62 patients with puerperal or postabortal genital infections. In all patients, the initial dose was 6 g/day. In 84% of patients, we found anaerobes in genital specimens. Of aerobic isolates, only enterococci were resistant. Among anaerobes tested, only two isolates (a Clostridium leptum and a Bacteroides disiens) had minimal inhibitory concentrations of greater than or equal to microgram/ml. Good clinical responses occurred in 56 of 62 (90%). Moxalactam was well tolerated with little local irritation and minimal hepatic, renal, or hematological abnormalities.
Insights
Moxalactam effectively treated genital infections in women, showing high clinical success rates and good tolerability. This antibiotic demonstrated significant activity against common anaerobic bacteria found in these infections.
Area of Science:
- Infectious Diseases
- Pharmacology
- Obstetrics & Gynecology
Background:
- Puerperal and postabortal genital infections are significant causes of morbidity in women.
- Anaerobic bacteria frequently play a crucial role in the pathogenesis of these infections.
- Effective antibiotic therapy is essential for managing these conditions.
Purpose of the Study:
- To evaluate the efficacy and safety of moxalactam in patients with puerperal or postabortal genital infections.
- To assess the antimicrobial activity of moxalactam against relevant aerobic and anaerobic pathogens.
- To determine the clinical response and tolerability of moxalactam treatment.
Main Methods:
- A clinical trial involving 62 patients with genital infections.
- Administration of moxalactam at an initial dose of 6 g/day.
- Microbiological analysis of genital specimens to identify aerobic and anaerobic isolates.
- Assessment of clinical response and adverse events.
Main Results:
- Moxalactam demonstrated excellent activity against anaerobic bacteria, with only two resistant isolates (Clostridium leptum, Bacteroides disiens).
- Enterococci were the only resistant aerobic isolates.
- A high clinical response rate of 90% (56 out of 62 patients) was observed.
- Moxalactam was well tolerated, with minimal local irritation and no significant hepatic, renal, or hematological abnormalities.
Conclusions:
- Moxalactam is an effective and well-tolerated antibiotic for treating puerperal and postabortal genital infections.
- Its potent activity against anaerobic pathogens makes it a valuable therapeutic option.
- Further research may explore moxalactam's role in broader gynecological and obstetric infections.